PhoreMost Ltd., a UK-based biopharma company dedicated to drugging ‘undruggable’ disease targets, has entered into a multi-project collaboration with Otsuka Pharmaceutical Co. Financial details were not disclosed.

PhoreMost will leverage its expertise and next-gen phenotypic screening platform, SITESEEKER, for disease relevant pathways selected by Otsuka. Novel targets identified will be further validated and characterized by Otsuka as part of its development pipeline, with an initial focus on gene therapy applications of identified targets.

PhoreMost’s SITESEEKER platform exploits protein shape diversity to find functionally active peptides, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or ‘PROTEINi’, technology PhoreMost uses SITESEEKER to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications.

Dr. Chris Torrance, chief executive officer of PhoreMost, said, “This collaboration with Otsuka is further recognition of the power of the SITESEEKER approach to drive the identification of novel, druggable targets. We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.”